Clinigen Group plc (AIM: CLIN, “Clinigen” or the “Group”), the global pharmaceuticals and services company, is holding a Capital Markets Day for institutional investors and analysts today in London.

The event is being hosted by Shaun Chilton, Group Chief Executive Officer, and will include presentations by senior executives, including representatives from each of the Group’s three businesses – Clinical Trial Services, Unlicensed Medicines and Commercial Medicines.

The presentations will cover a number of areas, including:

  • The market dynamics affecting each business and how the respective strategies are evolving to meet customers’ demands and provide long term growth
  • How the Group’s businesses are working in ever greater alignment to provide a continuation of specialised support throughout the lifecycle of a product
  • How Clinigen’s buy and build strategy along with its digital strategy is creating a global infrastructure to support each business and the Group’s future growth

No new material information will be provided.

A copy of the presentations and an audio recording of the day will be made available on the Group’s website at shortly after the event.

- Ends -

Contact Details

Clinigen Group plc 
Tel: +44 (0) 1283 495 010 
Shaun Chilton, Group Chief Executive Officer 
Matt Parrish, Head of Investor Relations

Numis Securities Limited 
Tel: +44 (0) 20 7260 1000 
Michael Meade / Freddie Barnfield (Nominated Adviser) 
James Black / Tom Ballard (Corporate Broking)

RBC Capital Markets – Joint Broker 
Tel: +44 (0) 20 7653 4000 
Marcus Jackson / Elliot Thomas

Instinctif Partners
Tel: +44 (0) 20 7457 2020 
Adrian Duffield / Melanie Toyne Sewell / Alex Shaw 

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.

For more information, please visit